Saturday 17 October 2026
Export AXGN’s income statement to Excel — free account
AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.1%, EPS fell 400.0%, free cash flow fell 17.4% and total debt fell 72.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
34.62
1.01
−2.83%
Follow AXGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (18.21%) | (17.96%) | (13.49%) | (1.90%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 5 | 5 | 6 | |
| (13.15%) | (12.95%) | (7.38%) | (1.03%) | ||
ROIC |
(4.99%) | (3.48%) | (3.25%) | 1.68% | |
Return on Tangible Assets |
(13.29%) | (13.01%) | (8.79%) | (1.24%) | |
Average Days of Receivables |
49.59 | 43.40 | 42.41 | 52.32 | |
Free Cash Flow per Share |
0.12 | 0.15 | (0.10) | 0.04 | |
Free Cash Flow |
6.51 | 7.66 | (4.78) | 2.06 | |
Capital Expenditures |
(8.54) | (7.90) | (5.59) | (4.45) | |
| Other line items | |||||
Cash ROIC |
1.68% | 2.08% | (1.98%) | 0.91% | |
Accounts Receivable Turnover |
8.08 | 8.72 | 8.96 | 7.75 | |
Accounts Payable Turnover |
2.50 | 2.73 | 2.32 | 2.31 | |
Inventory Turnover |
1.52 | 1.46 | 1.53 | 1.55 | |
Average Days of Payables |
162.19 | 146.61 | 133.65 | 172.92 | |
Days of Inventory on Hand |
270.22 | 282.66 | 267.33 | 273.34 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.35% | 14.41% | 14.60% | 12.67% | |
Selling, General and Administrative Expense of Revenue |
65.32% | 64.39% | 63.19% | 60.25% | |
Share Based Compensation of Revenue |
14.99% | 14.30% | 13.37% | 7.72% | |
Interest Coverage |
(3.08) | (1.47) | (1.02) | 0.51 | |
Operating CF/Net income |
(0.45) | (0.49) | (0.05) | (3.10) | |
Depreciation/Fixed assets |
0.12 | 0.11 | 0.11 | 0.10 | |
Capex/Depreciation |
(0.89) | (0.83) | (0.60) | (0.53) | |
Revenue per Share |
4.71 | 4.62 | 4.89 | 4.62 | |
Operating CF per Share |
0.28 | 0.30 | 0.02 | 0.14 | |
Capex per Share |
(0.16) | (0.15) | (0.12) | (0.10) | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 |
Columns are period end dates